Unichem Laboratories (NSEI:UNICHEMLAB) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

UNICHEMLAB Overzicht aandelen

Unichem Laboratories Limited, een farmaceutisch bedrijf, produceert en verkoopt wereldwijd farmaceutische producten.

UNICHEMLAB fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Risicoanalyse

De winst is de afgelopen 5 jaar met 36.8% per jaar gedaald

Unichem Laboratories Limited Concurrenten

RPG Life Sciences

NSEI:RPGLIFE

₹46.3b

Morepen Laboratories

BSE:500288

₹47.3b

Aarti Drugs

BSE:524348

₹46.0b

Gujarat Themis Biosyn

BSE:506879

₹35.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Unichem Laboratories
Historische aandelenkoersen
Huidige aandelenkoers	₹732.10
52 Week Hoogtepunt	₹754.20
52 Week Laag	₹399.00
Bèta	0.20
11 maand verandering	11.08%
3 maanden verandering	40.72%
1 Jaar Verandering	73.34%
33 jaar verandering	188.06%
5 jaar verandering	285.32%
Verandering sinds IPO	1,166.17%

Recent nieuws en updates

It's A Story Of Risk Vs Reward With Unichem Laboratories Limited (NSE:UNICHEMLAB)

Sep 13

Recent updates

It's A Story Of Risk Vs Reward With Unichem Laboratories Limited (NSE:UNICHEMLAB)

Sep 13

Optimistic Investors Push Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares Up 26% But Growth Is Lacking

Feb 06

There's Reason For Concern Over Unichem Laboratories Limited's (NSE:UNICHEMLAB) Massive 28% Price Jump

Jul 23

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Jul 15

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Jul 01

Unichem Laboratories (NSE:UNICHEMLAB) Is Making Moderate Use Of Debt

Nov 27

Investors Shouldn't Be Too Comfortable With Unichem Laboratories' (NSE:UNICHEMLAB) Robust Earnings

Jun 05

Should Unichem Laboratories Limited (NSE:UNICHEMLAB) Be Part Of Your Income Portfolio?

Mar 02

Unichem Laboratories Limited's (NSE:UNICHEMLAB) Stock's Been Going Strong: Could Weak Financials Mean The Market Will Correct Its Share Price?

Feb 09

Should You Take Comfort From Insider Transactions At Unichem Laboratories Limited (NSE:UNICHEMLAB)?

Jan 19

Do Institutions Own Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares?

Dec 29

Is Unichem Laboratories (NSE:UNICHEMLAB) Weighed On By Its Debt Load?

Dec 10

Key Things To Understand About Unichem Laboratories' (NSE:UNICHEMLAB) CEO Pay Cheque

Nov 23

Did Unichem Laboratories' (NSE:UNICHEMLAB) Share Price Deserve to Gain 41%?

Nov 02

Should You Buy Unichem Laboratories Limited (NSE:UNICHEMLAB) For Its 1.5% Dividend?

Oct 13

How Much Are Unichem Laboratories Limited (NSE:UNICHEMLAB) Insiders Spending On Buying Shares?

Sep 16

Is Unichem Laboratories (NSE:UNICHEMLAB) Using Too Much Debt?

Aug 26

Is Unichem Laboratories Limited's (NSE:UNICHEMLAB) Shareholder Ownership Skewed Towards Insiders?

Aug 05

Would Shareholders Who Purchased Unichem Laboratories'(NSE:UNICHEMLAB) Stock Three Years Be Happy With The Share price Today?

Jul 14

Rendement voor aandeelhouders

	UNICHEMLAB	IN Pharmaceuticals	IN Markt
7D	9.4%	-0.7%	0.3%
1Y	73.3%	59.6%	40.2%

Rendement versus industrie: UNICHEMLAB overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 59.7 % opleverde.

Rendement versus markt: UNICHEMLAB overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 44.6 %.

Prijsvolatiliteit

Is UNICHEMLAB's price volatile compared to industry and market?
UNICHEMLAB volatility
UNICHEMLAB Average Weekly Movement	5.7%
Pharmaceuticals Industry Average Movement	6.1%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.4%
10% least volatile stocks in IN Market	3.9%

Stabiele aandelenkoers: UNICHEMLAB heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van UNICHEMLAB is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1944	2,875	Pabitra Kumar Bhattacharya	www.unichemlabs.com

Unichem Laboratories Limited, een farmaceutisch bedrijf, produceert en verkoopt wereldwijd farmaceutische producten. Het bedrijf biedt formuleringsproducten voor verschillende therapeutische gebieden, zoals gastro-enterologie, cardiologie, diabetologie, psychiatrie, neurologie, antibacteriële en infectiewerende middelen en pijnbestrijding. Het bedrijf biedt ook actieve farmaceutische ingrediënten en contractproductiediensten aan.

Unichem Laboratories Limited Samenvatting

Hoe verhouden de winst en inkomsten van Unichem Laboratories zich tot de beurswaarde?
UNICHEMLAB fundamentele statistieken
Marktkapitalisatie	₹51.74b
Inkomsten(TTM)	-₹605.50m
Inkomsten(TTM)	₹17.28b

3.0x

P/S-verhouding

-85.4x

Koers/Winstverhouding

Is UNICHEMLAB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
UNICHEMLAB resultatenrekening (TTM)
Inkomsten	₹17.28b
Kosten van inkomsten	₹7.15b
Brutowinst	₹10.13b
Overige uitgaven	₹10.74b
Inkomsten	-₹605.50m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-8.60
Brutomarge	58.63%
Nettowinstmarge	-3.50%
Schuld/Eigen Vermogen Verhouding	10.5%

Hoe presteerde UNICHEMLAB op de lange termijn?

Bekijk historische prestaties en vergelijking

UNICHEMLAB Overzicht aandelen

Beloningen

Risicoanalyse

Unichem Laboratories Limited Concurrenten

NSEI:RPGLIFE

₹46.3b

BSE:500288

₹47.3b

BSE:524348

₹46.0b

BSE:506879

₹35.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

It's A Story Of Risk Vs Reward With Unichem Laboratories Limited (NSE:UNICHEMLAB)

Unichem Laboratories Limited to Report Q1, 2025 Results on Aug 08, 2024

High number of new directors

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Recent updates

It's A Story Of Risk Vs Reward With Unichem Laboratories Limited (NSE:UNICHEMLAB)

Unichem Laboratories Limited to Report Q1, 2025 Results on Aug 08, 2024

High number of new directors

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

New major risk - Revenue and earnings growth

Unichem Laboratories Limited to Report Q4, 2024 Results on May 22, 2024

Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023)

Optimistic Investors Push Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares Up 26% But Growth Is Lacking

Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024

Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg

Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023)

Unichem Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Insider recently sold ₹1.5m worth of stock

First quarter 2024 earnings released: ₹0.09 loss per share (vs ₹3.32 loss in 1Q 2023)

Non-Executive Independent Director recently sold ₹10m worth of stock

Full year 2023 earnings released: ₹28.72 loss per share (vs ₹4.70 profit in FY 2022)

Third quarter 2023 earnings released: ₹9.08 loss per share (vs ₹2.01 loss in 3Q 2022)

Is Unichem Laboratories (NSE:UNICHEMLAB) Using Debt Sensibly?

Krka Reportedly Eyes Promoter Stake in Unichem Laboratories

Insufficient new directors

Second quarter 2023 earnings released: ₹10.04 loss per share (vs ₹1.82 loss in 2Q 2022)

Unichem Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Unichem Laboratories Limited Receives ANDA Approval for Extended Phenytoin Sodium Capsules USP, 100 Mg from United States Food and Drug Administration

Does Unichem Laboratories (NSE:UNICHEMLAB) Have A Healthy Balance Sheet?

Unichem Laboratories Limited Receives ANDA Approval for Carbamazepine Tablets USP

Unichem Laboratories Limited Receives ANDA Approval for Its Quetiapine Extended-Release Tablets

Unichem Laboratories Limited Receives ANDA Approval for its Labetalol Hydrochloride Tablets, USP 100 Mg, 200 Mg, and 300 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited to Report Q1, 2023 Results on Aug 09, 2022

Unichem Laboratories (NSE:UNICHEMLAB) Is Due To Pay A Dividend Of ₹4.00

Upcoming dividend of ₹4.00 per share

There's Reason For Concern Over Unichem Laboratories Limited's (NSE:UNICHEMLAB) Massive 28% Price Jump

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Full year 2022 earnings released: EPS: ₹4.70 (vs ₹4.88 in FY 2021)

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Unichem Laboratories Limited, Annual General Meeting, Aug 09, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories Limited Recommends Final Dividend for the Year Ended March 31, 2022

Unichem Laboratories Limited to Report Q4, 2022 Results on May 27, 2022

Insufficient new directors

Unichem Laboratories Limited Receives ANDA Approval for Its Divalproex Sodium Extended-Release Tablet

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories (NSE:UNICHEMLAB) Is Making Moderate Use Of Debt

Second quarter 2022 earnings released: ₹1.82 loss per share (vs ₹1.24 profit in 2Q 2021)

Upcoming dividend of ₹4.00 per share

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Receives Tentative USFDA Approval for ANDA of Aripiprazole Tablets

Investors Shouldn't Be Too Comfortable With Unichem Laboratories' (NSE:UNICHEMLAB) Robust Earnings

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Recommends Dividend for the Year Ended March 31, 2021

Unichem Laboratories Limited Announces That It Has Received ANDA Approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg

Insider recently bought ₹2.3m worth of stock

Unichem Laboratories Limited Receives ANDA Approval for Its Guanfacine Tablets, USP 1 Mg and 2 Mg from the United States Food and Drug Administration